RT Journal Article
SR Electronic
T1 Clinical Evaluation of Tc-99m N,N′-Bis(Mercaptoacetyl)-2,3-Diaminopropanoate as a Replacement for I-131 Hippurate: Concise Communication
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 42
OP 48
VO 25
IS 1
A1 Klingensmith, W. C.
A1 Fritzberg, A. R.
A1 Spitzer, V. M.
A1 Johnson, D. L.
A1 Kuni, C. C.
A1 Williamson, M. R.
A1 Washer, G.
A1 Weil, R.
YR 1984
UL http://jnm.snmjournals.org/content/25/1/42.abstract
AB A clinical comparison of Tc-99m N,N′-bis(mercaptoacetyl)-2,3-diaminopropanoate (Component A) (Tc-99m CO2-DADS-A) and I-131 hippurate was conducted in a series of five normal volunteers and 18 patients. Each subject was studied in one session with Tc-99m CO2-DADS-A and I-131-hippurate; digital and analog images were recorded for 30 min and after voiding. In the normal volunteers, digital images with Tc-99m CO2-DADS-A gave a kidney-to-background ratio at 3 min that was greater relative to I-131 hippurate, a leading-edge parenchymal transit time that was similar to I-131 hippurate, and a percent injected dose in the urine at 30 min that was slightly less than I-131 hippurate (p <0.05). In patients (serum creatinine 1.0 to 14.3 mg/dl), deceasing renal function impaired excretion of Tc-99m CO2-DADS-A more than that of I-131 hippurate (p <0.01). In analog images, Tc-99m CO2-DADS-A always gave superior spatial resolution. No evidence of hepatobiliary excretion was detected with either radiopharmaceutical. We conclude that Tc-99m CO2-DADS-A and similar compounds should be pursued as possible replacements for I-131 hippurate.